Boss of OIive Garden owner doesn't think Ozempic will tank revenue

The boss of Olive Garden's parent company has dismissed concerns that popular weight-loss drug Ozempic might decrease customer demand.

'Full-service dining occasions are driven by a desire to connect with family and friends,' Rick Cardenas, CEO of Darden Restaurants, said on an earnings call last month.

He added that he did not expect appetite suppressant drugs to have a 'meaningful impact' on the company, which has carefully crafted its menus over the years to give guests a range of options.

Load More